Release
2024/01/09
OSAKA, Japan, January 9, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and NTT DATA Japan Corporation (Head Office: Tokyo, Japan; Representative Director, President: Yutaka Sasaki; hereafter "NTT DATA Japan"), NTT DATA KANSAI Corporation (Head Office: Osaka, Japan; President: Yoshihiro Saito; hereafter "NTT DATA KANSAI"), and QUNIE CORPORATION (Head Office: Tokyo, Japan; President and Chief Executive Officer: Shigeki Yamaguchi; hereafter "QUNIE") announce the initiation of cooperative construction of the "DTx Distribution Platform" (hereafter "the Platform") for the promotion of Digital Therapeutics services (hereafter "DTx*") that provide treatment through mobile applications and other means.
* DTx：Digital Therapeutics
DTx, or Digital Therapeutics, refers to digital products that provide evidence-based therapeutic interventions for the treatment, management, and prevention of diseases and conditions. It is expected to be a new modality in a wide range of medical and healthcare fields. However, since the process of prescribing DTx differs from that of conventional medical pharmaceuticals, there is a need to consider and establish new mechanisms to deliver DTx to patients safely and efficiently. In addition, healthcare institutions and DTx providers typically have individual contracts on a one-to-one basis for prescription registration and billing. However, if the contract processes and payment specifications vary among providers, it may become burdensome for healthcare institutions to handle administrative procedures. Therefore, Shionogi, NTT DATA Japan, NTT DATA KANSAI, and QUNIE have decided to collaborate in the construction and standardization of an information infrastructure platform to promote the dissemination of DTx.
The launch of the Platform is scheduled for 2025. This Platform aims to standardize and centralize the coordination of necessary information between patients, healthcare institutions, and DTx providers. It consolidates various functions such as contracts, billing, and prescription registration between healthcare institutions and DTx providers, aiming to reduce the burden on both parties and establish a safer and more efficient prescription and distribution system.
Shionogi, NTT DATA Japan, NTT DATA KANSAI, and QUNIE will continue to collaborate and cooperate with government agencies and companies that share the same vision to contribute to the dissemination of DTx through the construction of this Platform.
About NTT DATA
NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernization and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.
About NTT DATA KANSAI
NTT DATA KANSAI provides IT solutions and services to customers not only in the Kansai region but also nationwide and internationally. Leveraging the diverse range of products, services, and expertise within the NTT DATA Group, NTT DATA KANSAI offers comprehensive services including IT consulting to envision customers' IT systems, providing optimal information systems and services, supporting post-implementation, and assisting with IT utilization strategies.
In the medical and healthcare industry, NTT DATA KANSAI is engaged in creating and providing new services across various sectors, including government, insurance, and pharmaceutical companies, to contribute to the realization of a better society.
URL：https://www.nttdata-kansai.co.jp/
About QUNIE
As a member of NTT DATA Group, we, QUNIE CORPORATION, partners with various clients who strive to implement business transformation. Through a wide range of consulting services, we provide professional excellence, advanced business expertise and experiential innovation on a global scale.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html